Immuno-prevention of Rh hemolytic disease of the newborn.
D000028:Abortion, Induced; D000022:Abortion, Spontaneous; D000917:Antibody Formation; D001666:Binding Sites, Antibody; D001667:Binding, Competitive; D001787:Blood Group Incompatibility / Q000628:therapy; D000939:Epitopes; D004899:Erythroblastosis, Fetal / Q000517:prevention & control*; D005260:Female; D005865:Gestational Age; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007165:Immunosuppression Therapy; D007231:Infant, Newborn; D007273:Injections, Intramuscular; D007518:Isoantibodies; D008431:Maternal-Fetal Exchange; D007744:Obstetric Labor Complications; D049590:Postpartum Period; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000628:therapy; D012204:Rh-Hr Blood-Group System; D065227:Transfusion Reaction; D014592:Uterine Hemorrhage / Q000517:prevention & control
D000939:Epitopes; D007074:Immunoglobulin G; D007518:Isoantibodies; D012204:Rh-Hr Blood-Group System